Editors' ChoiceMEDICINE

Paper of note in Science Translational Medicine

See allHide authors and affiliations

Sci. Signal.  07 Jun 2016:
Vol. 9, Issue 431, pp. ec136
DOI: 10.1126/scisignal.aag2796

CARDIOVASCULAR GENOMICS

At risk by association

A missense variant in GLP1R associated with lower fasting glucose levels and protective against type 2 diabetes is associated with lower risk of coronary heart disease, suggesting that GLP1R agonists are not associated with an unacceptable increase in cardiovascular risk.

R. A. Scott, D. F. Freitag, L. Li, A. Y. Chu, P. Surendran, R. Young, N. Grarup, A. Stancáková, Y. Chen, T. V. Varga, H. Yaghootkar, J. Luan, J. H. Zhao, S. M. Willems, J. Wessel, S. Wang, N. Maruthur, K. Michailidou, A. Pirie, S. J. van der Lee, C. Gillson, A. A. Al Olama, P. Amouyel, L. Arriola, D. Arveiler, I. Aviles-Olmos, B. Balkau, A. Barricarte, I. Barroso, S. B. Garcia, J. C. Bis, S. Blankenberg, M. Boehnke, H. Boeing, E. Boerwinkle, I. B. Borecki, J. Bork-Jensen, S. Bowden, C. Caldas, M. Caslake, The CVD50 consortium, L. A. Cupples, C. Cruchaga, J. Czajkowski, M. den Hoed, J. A. Dunn, H. M. Earl, G. B. Ehret, E. Ferrannini, J. Ferrieres, T. Foltynie, I. Ford, N. G. Forouhi, F. Gianfagna, C. Gonzalez, S. Grioni, L. Hiller, J.-H. Jansson, M. E. Jørgensen, J. W. Jukema, R. Kaaks, F. Kee, N. D. Kerrison, T. J. Key, J. Kontto, Z. Kote-Jarai, A. T. Kraja, K. Kuulasmaa, J. Kuusisto, A. Linneberg, C. Liu, G. Marenne, K. L. Mohlke, A. P. Morris, K. Muir, M. Müller-Nurasyid, P. B. Munroe, C. Navarro, S. F. Nielsen, P. M. Nilsson, B. G. Nordestgaard, C. J. Packard, D. Palli, S. Panico, G. M. Peloso, M. Perola, A. Peters, C. J. Poole, J. R. Quirós, O. Rolandsson, C. Sacerdote, V. Salomaa, M.-J. Sánchez, N. Sattar, S. J. Sharp, R. Sims, N. Slimani, J. A. Smith, D. J. Thompson, S. Trompet, R. Tumino, D. L. van der A, Y. T. van der Schouw, J. Virtamo, M. Walker, K. Walter, GERAD_EC Consortium, Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), Alzheimer’s Disease Genetics Consortium, Pancreatic Cancer Cohort Consortium, European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD),EPIC-InterAct, J. E. Abraham, L. T. Amundadottir, J. L. Aponte, A. S. Butterworth, J. Dupuis, D. F. Easton, R. A. Eeles, J. Erdmann, P. W. Franks, T. M. Frayling, T. Hansen, J. M. M. Howson, T. Jørgensen, J. Kooner, M. Laakso, C. Langenberg, M. I. McCarthy, J. S. Pankow, O. Pedersen, E. Riboli, J. I. Rotter, D. Saleheen, N. J. Samani, H. Schunkert, P. Vollenweider, S. O’Rahilly, CHARGE consortium, The CHD Exome+ Consortium, CARDIOGRAM Exome Consortium, P. Deloukas, J. Danesh, M. O. Goodarzi, S. Kathiresan, J. B. Meigs, M. G. Ehm, N. J. Wareham, D. M. Waterworth, A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci. Transl. Med. 8, 341ra76 (2016). [Abstract]